Contrarily, previous studies have shown significant associations between this marker and amyloid pathology (as measured by CSF or PET), which were stronger than those with tau pathology (also measured with CSF or PET; Benedet et al, 2021; Pereira et al, 2021). Here, MAPT is linked to amyloidosis.